Gamma polyglutamated lometrexol and uses thereof
AssigneeL.E.A.F. Holdings Group LLC
InventorsClet NIYIKIZA, Victor Mandla MOYO
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to gamma polyglutamated lometrexol compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated lometrexol, and methods of making and using the gamma polyglutamated lometrexol compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).
Claims64
A liposomal composition comprising a gamma polyglutamated lometrexol encapsulated by a liposome.
-12. (canceled)
(canceled)
-20. (canceled)
(canceled)
-26. (canceled)
-30. (canceled)
(canceled)
-37. (canceled)
-46. (canceled)
(canceled)
(canceled)
The liposomal composition of claim 25, wherein the pegylated liposome comprises from 1 to 1000 or 30-200 targeting moieties.
The liposomal composition of claim 25, further comprising one or more of an immunostimulatory agent, a detectable marker and a maleimide, wherein the immunostimulatory agent, the detectable marker or the maleimide is attached to said PEG or the exterior of the liposome.
(canceled)
-63. (canceled)
-66. (canceled)
-72. (canceled)
(canceled)
(canceled)
-82. (canceled)
(canceled)
(canceled)
A method for treating an infectious disease that comprises administering an effective amount of the composition of to a subject having or at risk of having an infectious disease.
(canceled)
-94. (canceled)
Dependencies are inferred from the claim text.